Company intelligence / Profile preview

Nautilus Neurosciences

Bridgewater, New Jersey, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

CAMBIA (diclofenac potassium oral solution) was launched in 2010 for acute migraine; demonstrated rapid onset of relief in clinical studies, including pain, nausea, and photophobia/phonophobia. US rights and commercialization acquired by Depomed in 2013 for $48.7 million

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Depomed (acquirer of main product rights)

Beyond the preview

Go deeper on Nautilus Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nautilus Neurosciences.

Explore the full profile